Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE

ABSTRACT: Key Points • Median platelet count increased to ≥50 × 103/μL at month 2 after starting eltrombopag and stayed at 70 × 103/μL to 100 × 103/μL thereafter.• Compliance to prescribed eltrombopag dose since the previous routine visit was ≥96.0%. Visual Abstract Abstract CITE was a prospective, noninterventional study in adult patients with chronic immune thrombocytopenia treated with eltrombopag under routine clinical care in Asia-Pacific, the Middle East, and Turkey. Data to assess eltrombopag usage, compliance, and outcomes were collected from May 2017 to December 2020. Platelet response was defined as platelet count ≥50 × 103/μL in the absence of rescue medications and splenectomy. Quality of life was evaluated using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) que

SUBMITTER: Wong R 

PROVIDER: S-EPMC10469381 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature